ORXOFOrexo AB

About Orexo AB (ORXOF)

Orexo AB (ORXOF) is a Drug Manufacturers - Specialty & Generic company headquartered in Stockholm, Uppsala, Sweden whose shares trade over-the-counter on the OTCQX tier.

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX market (ORXOY) in the US.

Products and services

Orexo develops improved pharmaceuticals by combining well-known and well-documented substances with in- house innovative drug delivery technologies. Since Orexo was founded in 1995, four pharmaceutical products have been developed; Diabact® for diagnosing of the gastric ulcer bacterium helicobacter pylori,¹ Abstral® for breakthrough cancer pain, Edluar® for insomnia and Zubsolv® for opioid use disorder (OUD). The last three mentioned are built on the first-generation drug delivery platform – the sub lingual. Thanks to successful partnerships, these products have been approved in multiple markets and helped patients benefit from improved drugs worldwide. Orexo’s next-generation drug delivery platform, AmorphOX®, has unique properties for the development of differentiated pharmaceuticals that need to be absorbed rapidly by the body and remain stable over time. The technology can be applied to a broad scope of active substances and is the backbone of the development of clinical stage rescue medications and multiple early-stage projects. For pharmaceuticals that go beyond Orexo’s key therapeutic areas, the company intends to initiate development and commercialization partnerships. (1) Diabact was divested at the time of the sale of the subsidiary Kibion in 2015

ORXOF key facts

Ticker symbol

ORXOF

Market tier

OTCQX

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Stockholm, Uppsala, Sweden

Country of incorporation

SE

Year of incorporation

1995

Employees

110

Estimated market cap

$37.49M (as of May 13, 2025)

Shares outstanding

34,710,639

Reporting standard

International Reporting: Nasdaq OMX Nordic Exchange Stockholm

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Mar 31, 2025)

Orexo AB leadership

• Nikolaj Sorensen — CEO
• Robert A. DeLuca — President, Subsidiary
• Fredrik Jarrsten — CFO
• Janne Laine — Treasurer

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with O